Company research
Sensus Healthcare, Inc.
CIK 1494891Updated Nov 13, 2026
SecuritySRTS · NASDAQ · equity
Historical securities (1)
SRTSW · NASDAQ · warrant · closed Dec 3, 2024Name history
Sensus Healthcare, LLC · through Dec 30, 2015
SRTS price & chart
Loading TradingView…
NASDAQ:SRTS on TradingView ↗About the company
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
In the news
No coverage from other publishers is available.
Seeking Alpha
Sensus Healthcare, Inc. (SRTS) Q3 2026 Earnings Call Transcript ↗
Sensus outlines shift to $250,000 average selling price as it targets a stronger second half ↗
SEC disclosures
Sensus Healthcare, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
SD filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 58,295,000Source | 59,858,000Source | 41,259,000Source | 58,852,000Source | 58,163,000Source | 51,546,000Source | 60,210,000Source | 57,273,000Source | 53,039,000Source | 62,165,000Source | 53,710,000Source | 56,735,000Source |
| Property, Plant and Equipment, NetUSD | 2,522,000Source | 1,635,000Source | 2,748,000Source | 2,714,000Source | 712,000Source | 2,314,000Source | 2,678,000Source | 633,000Source | 1,976,000Source | 1,997,000Source | 464,000Source | 243,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 50,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 24,453,000Source | 22,558,000Source | 15,186,000Source | 22,162,000Source | 18,972,000Source | 18,327,000Source | 19,072,000Source | 14,728,000Source | 22,083,000Source | 22,056,000Source | 23,148,000Source | 25,520,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,336,000Source | 16,961,000Source | 1,680,000Source | 12,622,000Source | 18,293,000Source | 3,578,000Source | 18,018,000Source | 19,625,000Source | 6,041,000Source | 19,731,000Source | 10,645,000Source | 17,299,000Source |
| Inventory, NetUSD | 13,040,000Source | 11,968,000Source | 18,459,000Source | 12,405,000Source | 12,769,000Source | 16,500,000Source | 9,923,000Source | 14,720,000Source | 14,563,000Source | 10,097,000Source | 11,861,000Source | 3,501,000Source |
| Assets, CurrentUSD | 50,205,000Source | 54,806,000Source | 37,677,000Source | 52,219,000Source | 54,473,000Source | 42,590,000Source | 54,196,000Source | 53,913,000Source | 45,892,000Source | 56,738,000Source | 49,528,000Source | 53,241,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 6,921,000Source |
| Operating Lease, Right-of-Use AssetUSD | 513,000Source | 630,000Source | 329,000Source | 574,000Source | 679,000Source | 390,000Source | 633,000Source | 726,000Source | 452,000Source | 581,000Source | 774,000Source | 996,000Source |
| Other Assets, NoncurrentUSD | 818,000Source | 590,000Source | 505,000Source | 535,000Source | 655,000Source | 566,000Source | 616,000Source | 688,000Source | 640,000Source | 652,000Source | 804,000Source | 468,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,101,000Source | 5,727,000Source | 4,396,000Source | 6,788,000Source | 5,262,000Source | 6,004,000Source | 7,176,000Source | 6,066,000Source | 4,941,000Source | 6,338,000Source | 4,868,000Source | 8,666,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source | 169,000Source |
| Additional Paid in CapitalUSD | 46,014,000Source | 45,640,000Source | 46,230,000Source | 45,941,000Source | 45,578,000Source | 46,160,000Source | 45,874,000Source | 45,496,000Source | 46,090,000Source | 45,795,000Source | 45,405,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | 8,882,000Source | 11,888,000Source | -5,660,000Source | 9,825,000Source | 10,673,000Source | 3,089,000Source | 10,862,000Source | 9,061,000Source | 5,715,000Source | 13,434,000Source | 6,787,000Source | 6,302,000Source |
| Stockholders' Equity Attributable to ParentUSD | 51,194,000Source | 54,131,000Source | 36,863,000Source | 52,064,000Source | 52,901,000Source | 45,542,000Source | 53,034,000Source | 51,207,000Source | 48,098,000Source | 55,827,000Source | 48,842,000Source | 48,069,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 45,031,000Source |
| Liabilities and EquityUSD | 58,295,000Source | 59,858,000Source | 41,259,000Source | 58,852,000Source | 58,163,000Source | 51,546,000Source | 60,210,000Source | 57,273,000Source | 53,039,000Source | 62,165,000Source | 53,710,000Source | 56,735,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,803,000Source | 5,210,000Source | 4,327,000Source | 6,413,000Source | 4,682,000Source | 5,859,000Source | 6,725,000Source | 5,473,000Source | 4,722,000Source | 5,885,000Source | 4,212,000Source | 7,697,000Source |
| Operating Lease, Liability, CurrentUSD | 257,000Source | 200,000Source | 274,000Source | 252,000Source | 195,000Source | 267,000Source | 246,000Source | 191,000Source | 262,000Source | 204,000Source | 187,000Source | 190,000Source |
| Operating Lease, Liability, NoncurrentUSD | 277,000Source | 451,000Source | 69,000Source | 343,000Source | 503,000Source | 141,000Source | 408,000Source | 553,000Source | 209,000Source | 398,000Source | 596,000Source | 830,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 663,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | 648,000Source | — | 619,000Source | 529,000Source | — | 639,000Source | 550,000Source | 948,000Source | 842,000Source | 541,000Source | 657,000Source | 693,000Source |
| Deferred Revenue, NoncurrentUSD | 21,000Source | — | — | 32,000Source | — | 4,000Source | 43,000Source | 40,000Source | 10,000Source | 55,000Source | 60,000Source | 139,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 12,000Source | 21,000Source | 17,000Source | 1,713,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | 86,000Source | 99,000Source | 96,000Source | 86,000Source | 400,000Source | 239,000Source | 275,000Source | 315,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 70,000Source | 79,000Source | 295,000Source | 323,000Source | 328,000Source | 187,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -2,463,000Source | -1,713,000Source | -13,646,000Source | 9,209,000Source | -6,647,000Source | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 2,368,000Source | 586,000Source | 4,635,000Source | -268,000Source | 8,577,000Source | 3,191,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -1,607,000Source | 110,000Source | -1,882,000Source | -57,000Source | -427,000Source | -1,713,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,753,000Source | -2,677,000Source | 528,000Source | -831,000Source | -2,145,000Source | -1,412,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,000Source | -7,000Source | -196,000Source | -276,000Source | -187,000Source | 14,841,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,000Source | 7,000Source | 196,000Source | 276,000Source | 229,000Source | 159,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 5,000Source | 52,000Source | 59,000Source | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | 300,000Source | 300,000Source | — | 27,000Source | 2,999,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | -300,000Source | -305,000Source | 15,000Source | -40,000Source | -2,428,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 24,453,000Source | 22,558,000Source | 15,186,000Source | 22,162,000Source | 18,327,000Source | 19,072,000Source | 22,083,000Source | 22,056,000Source | 23,148,000Source | 25,520,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 2,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 980,000Source | 2,582,000Source | 1,440,000Source | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 194,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 0Source | 0Source | — | 5,000Source | — | 0Source | 5,000Source | 2,000Source | 31,000Source | — |
| DepreciationUSD | — | — | 98,000Source | 53,000Source | — | — | 96,000Source | 86,000Source | 386,000Source | 200,000Source | 226,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 42,000Source | -197,000Source |
| Gain (Loss) on Sale of PropertiesUSD | — | — | — | — | — | — | — | — | — | — | — | 12,779,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 12,779,000Source |
| General and Administrative ExpenseUSD | — | — | — | 1,573,000Source | — | — | — | — | — | — | 5,156,000Source | 5,008,000Source |
| Income Tax Expense (Benefit)USD | — | — | -1,466,000Source | 559,000Source | 5,686,000Source | -723,000Source | -1,607,000Source | 110,000Source | -1,905,000Source | 2,375,000Source | 167,000Source | 3,746,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -943,000Source | 1,215,000Source | -8,749,000Source | -1,037,000Source | -2,626,000Source | -2,572,000Source | -7,719,000Source | 6,647,000Source | 485,000Source | 24,244,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 13,159,000Source |
| Operating ExpensesUSD | — | — | 5,282,000Source | 3,745,000Source | 3,949,000Source | 4,846,000Source | 5,349,000Source | 7,000,000Source | 22,174,000Source | 16,341,000Source | 14,442,000Source | 14,797,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 201,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 160,000Source | 279,000Source | 117,000Source | 183,000Source | 125,000Source | 184,000Source | 683,000Source | 932,000Source | 1,034,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 67,000Source | 46,000Source | — |
| Investment Income, Interest | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Operating Lease, Lease Income | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 6,884,000Source | 8,839,000Source | 2,290,000Source | 7,315,000Source | 3,394,000Source | 8,344,000Source | 27,482,000Source | 41,807,000Source | 24,405,000Source | 44,532,000Source |
| Cost of RevenueUSD | — | — | 4,171,000Source | 3,599,000Source | 1,521,000Source | 4,412,000Source | 2,403,000Source | 3,990,000Source | 15,615,000Source | 17,376,000Source | 10,345,000Source | 14,904,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 1,917,000Source | 1,573,000Source | 1,786,000Source | 1,986,000Source | 2,043,000Source | 2,208,000Source | 7,873,000Source | 7,147,000Source | — | — |
| Operating Income (Loss)USD | — | — | -2,569,000Source | 1,495,000Source | -3,180,000Source | -1,943,000Source | -4,358,000Source | -2,646,000Source | -10,307,000Source | 8,090,000Source | -382,000Source | 14,831,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 160,000Source | 279,000Source | 117,000Source | 183,000Source | 125,000Source | 184,000Source | 683,000Source | 932,000Source | 1,034,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,409,000Source | 1,774,000Source | -3,063,000Source | -1,760,000Source | -4,233,000Source | -2,462,000Source | -9,624,000Source | 9,022,000Source | 652,000Source | 27,990,000Source |
| Income Tax Expense (Benefit)USD | — | — | -1,466,000Source | 559,000Source | 5,686,000Source | -723,000Source | -1,607,000Source | 110,000Source | -1,905,000Source | 2,375,000Source | 167,000Source | 3,746,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -943,000Source | 1,215,000Source | -8,749,000Source | -1,037,000Source | -2,626,000Source | -2,572,000Source | -7,719,000Source | 6,647,000Source | 485,000Source | 24,244,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.06Source | 0.07Source | -0.53Source | -0.06Source | -0.16Source | -0.16Source | -0.47Source | 0.41Source | 0.03Source | 1.47Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.06Source | 0.07Source | -0.53Source | -0.06Source | -0.16Source | -0.16Source | -0.47Source | 0.41Source | 0.03Source | 1.46Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 16,320,036Source | 16,321,131Source | 16,462,059Source | 16,320,036Source | 16,462,653Source | 16,341,867Source | 16,326,937Source | 16,312,351Source | 16,259,254Source | 16,480,991Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 16,320,036Source | 16,345,749Source | 16,462,059Source | 16,320,036Source | 16,462,653Source | 16,341,867Source | 16,326,937Source | 16,359,616Source | 16,266,139Source | 16,618,214Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | 86,000Source | 99,000Source | 96,000Source | 86,000Source | 400,000Source | 239,000Source | 275,000Source | — |
| General and Administrative ExpenseUSD | — | — | — | 1,573,000Source | — | — | — | — | — | — | 5,156,000Source | 5,008,000Source |
| Gross ProfitUSD | — | — | 2,713,000Source | 5,240,000Source | 769,000Source | 2,903,000Source | 991,000Source | 4,354,000Source | 11,867,000Source | 24,431,000Source | 14,060,000Source | 29,628,000Source |
| Interest ExpenseUSD | — | — | — | — | — | -183,000Source | — | -184,000Source | — | -932,000Source | -992,000Source | 2,000Source |
| Interest Income (Expense), NetUSD | — | — | 160,000Source | 279,000Source | 117,000Source | 183,000Source | 125,000Source | 184,000Source | 683,000Source | — | — | — |
| Interest Income, OtherUSD | — | — | — | — | — | — | — | — | — | — | — | 382,000Source |
| Lease IncomeUSD | — | — | 530,000Source | — | 324,000Source | 358,000Source | 343,000Source | 199,000Source | 1,721,000Source | 247,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 13,159,000Source |
| Operating ExpensesUSD | — | — | 5,282,000Source | 3,745,000Source | 3,949,000Source | 4,846,000Source | 5,349,000Source | 7,000,000Source | 22,174,000Source | 16,341,000Source | 14,442,000Source | 14,797,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 201,000Source | — |
| Research and Development ExpenseUSD | — | — | 1,819,000Source | 863,000Source | 1,109,000Source | 1,471,000Source | 1,590,000Source | 2,606,000Source | 7,778,000Source | 4,216,000Source | 3,678,000Source | 3,460,000Source |
| Selling and Marketing ExpenseUSD | — | — | 1,546,000Source | 1,309,000Source | 1,054,000Source | 1,389,000Source | 1,716,000Source | 2,186,000Source | 6,523,000Source | 4,978,000Source | 5,608,000Source | 6,329,000Source |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Investment Income, Interest | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Operating Lease, Lease Income | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
g086026_ex99-1.htm · 8-K · 2026-11-12
Exhibit 99.1 Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy Increasing Patient Awareness and International Commercial Activities Create Additional Growth Opportunities BOCA RATON, Fla., November 12, 2026 - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed…
Read attachment ↗g085863_ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 g085863_ex99-1.htm EXHIBIT 99-1 Exhibit 99.1 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights Commercial Momentum Builds Following CPT Code Implementation Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing CMS Proposed 26% Increase in Hospital-Based Delivery Code, Further Strengthening the Reimbursement Outlook for SRT Customer Adoption, Pipeline Development and Commercial Expansion Advanced Across…
Read attachment ↗g085707_ex99-1.htm · 8-K · 2026-05-07
EX-99.1 2 g085707_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights Dedicated CPT Codes for Superficial Radiotherapy (SRT) Now Effective, Driving Increased Customer Activity, Customer Diversification and Improved Physician Economics Sales Pipeline and Financing Activity Strengthen Following Reimbursement Clarity Expansion of Installed Base and Recurring Revenue Growth Driving Advancement Towards Profitability Exit…
Read attachment ↗g085130_ex99-1.htm · 8-K · 2026-02-12
Exhibit 99.1 Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer 2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026 ──────────────────────────────────────────────────────────────────────────────────────────────────────────── Company enters 2026 with reimbursement certainty and strategic visibilit…
Read attachment ↗g085076_ex99-1.htm · 8-K · 2026-01-12
EX-99.1 2 g085076_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sensus Healthcare Appoints Larry Biscotti to its Board of Directors BOCA RATON, Fla. - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Heal…
Read attachment ↗g085016_ex99-1.htm · 8-K · 2025-11-13
EX-99.1 2 g085016_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Sensus Healthcare Appoints Eric Sachetta to its Board of Directors Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence BOCA RATON, Fla. (November 12, 2025) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncologica…
Read attachment ↗